Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.

Ye ZhuKristi M SwansonRicardo L RojasZhen WangJennifer L St SauverSue L VisscherLarry J ProkopSuzette J BielinskiLiewei WangRichard WeinshilboumBijan J Borah

Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2019)

We found mixed evidence on the cost-effectiveness of PGx in CVD care. Supportive evidence exists for clopidogrel-CYP2C19 and warfarin-CYP2C9/VKORC1, but evidence is limited in other drug-gene combinations. Gaps persist, including unclear explanation of perspective and cost inputs, underreporting of study design elements critical to economic evaluations, and limited examination of PGx panel and pre-emptive testing for their cost-effectiveness. This review identifies the need for further research on economic evaluations of PGx implementation.

Keyphrases

systematic review
healthcare
cardiovascular disease
primary care
genome wide
palliative care
emergency department
venous thromboembolism
meta analyses
transcription factor
pain management
chronic pain
adverse drug
combination therapy
direct oral anticoagulants
replacement therapy